Tuberculosis during JAK inhibitor or TNF-α inhibitors therapy: a disproportionality analysis from WHO pharmacovigilance database.

Maitre T, Bihan K, Veziris N, Godet C, Parrot A, Djibre M, Lebrun Vignes B, Cadranel J

Open source

DOI
10.1136/thorax-2025-223332
Published
2026 Sep 9
Container
Thorax
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/thorax-2025-223332,
  title = {Tuberculosis during JAK inhibitor or TNF-α inhibitors therapy: a disproportionality analysis from WHO pharmacovigilance database.},
  author = {Maitre T and Bihan K and Veziris N and Godet C and Parrot A and Djibre M and Lebrun Vignes B and Cadranel J},
  year = {2026},
  journal = {Thorax},
  doi = {10.1136/thorax-2025-223332},
  url = {https://doi.org/10.1136/thorax-2025-223332}
}

RIS

TY  - JOUR
TI  - Tuberculosis during JAK inhibitor or TNF-α inhibitors therapy: a disproportionality analysis from WHO pharmacovigilance database.
AU  - Maitre T
AU  - Bihan K
AU  - Veziris N
AU  - Godet C
AU  - Parrot A
AU  - Djibre M
AU  - Lebrun Vignes B
AU  - Cadranel J
PY  - 2026
JO  - Thorax
DO  - 10.1136/thorax-2025-223332
UR  - https://doi.org/10.1136/thorax-2025-223332
ER  - 

APA

T, M., K, B., N, V., C, G., A, P., M, D., B, L. V., & J, C. (2026). Tuberculosis during JAK inhibitor or TNF-α inhibitors therapy: a disproportionality analysis from WHO pharmacovigilance database.. Thorax. https://doi.org/10.1136/thorax-2025-223332

Source records